Streptococcus pneumoniae is a major cause of bacterial meningitis, septicemia, and pneumonia, and is responsible for almost a million childhood deaths worldwide, with 11% of all deaths occurring in children <5 years of age [1] . In England and Wales, prior to routine vaccination, the incidence of invasive pneumococcal disease (IPD) was highest in <2-year-olds (36/100 000 in [2005] [2006] ) and the serotypes included in the 7-valent pneumococcal conjugate vaccine (PCV7) were responsible for 73% of IPD [2] .
The United Kingdom introduced PCV7 into the routine childhood immunization schedule on 4 September 2006, at 2 and 4 months, with a booster at 12-13 months [2] . At the same time, a 12-month catch-up campaign was initiated for children up to 24 months of age [3] . From 1 April 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7, which aimed to protect against 6 additional pneumococcal serotypes [4] .
Both vaccines have been highly effective in preventing IPD caused by the vaccine serotypes across all age groups through direct and indirect (herd) protection, which was achieved by reducing acquisition of carriage in toddlers and, consequently, interrupting transmission to older children and adults [4] . The reduction in PCV-type IPD was offset by a small increase in IPD caused by nonvaccine serotypes (NVTs) but, 8 years after PCV7 introduction, there has been a 56% reduction in overall IPD incidence in England and Wales compared with the pre-PCV7 baseline [4] .
In industrialized countries with established PCV programs, IPD-related deaths in children are uncommon, with reported case fatality rates (CFRs) of <5% [5] , but increase in children with underlying diseases. Little is known about the children who die of IPD and whether the PCVs have had any impact on IPD-related deaths. This study aimed to describe the epidemiological and clinical characteristics of children who died of IPD during the first 8 years after PCV introduction in England and Wales.
Public Health England (PHE) initiated enhanced IPD surveillance in vaccine-eligible children in England and Wales following the introduction of the PCV7 on 4 September 2006. National Health Service (NHS) laboratories in England and Wales routinely submit all invasive pneumococcal isolates to the PHE national reference laboratory (NRL) for confirmation and serotyping; currently, >90% of invasive isolates nationally are serotyped by the NRL [5] . All children in the age group targeted for vaccination (ie, born since 4 September 2004 and diagnosed between 4 September 2006 and 3 September 2014) and aged <5 years at diagnosis are actively followed up using postal questionnaires to the child's general practitioner and hospital pediatrician, requesting information about vaccination history, comorbidities, clinical presentation, and outcomes of IPD. Case ascertainment in vaccine-eligible children has remained consistently high since PCV7 introduction as serotyping of invasive isolates has direct impact on clinical management, owing to its critical importance in identifying vaccine failure cases.
Fatal Cases
Fatal cases were identified from the general practitioner/clinician questionnaires, the Patient Demographic Service (a national database of NHS patients, https://digital.nhs.uk/demographics) and electronic death registrations records provided by the Office for National Statistics (www.statistics.gov.uk) to PHE for surveillance purposes. For all fatal cases, the final hospital discharge summary, including the cause of death as recorded on the death certificate, was requested. In England and Wales all childhood deaths, including those who died outside the hospital, are referred to the coroner and subjected to a postmortem, unless there was an irrefutable cause of death at the time of reporting (eg, a child with confirmed pneumococcal meningitis who died in hospital). For fatal cases undergoing postmortem examination, the coroner was contacted for the postmortem report, which also contained the cause of death. Deaths were considered to be IPD-related if a child had a pure growth of Streptococcus pneumoniae isolated within 30 days from a normally sterile site before or after death, with clinical, radiological, and/or histopathological evidence of invasive bacterial infection and after other differential diagnoses were appropriately excluded. Children with IPD who survived their infection and later died of other cases were excluded from the analysis, as were stillbirths and septic abortions.
Meningitis was defined as S. pneumoniae identified (culture/ polymerase chain reaction) in the cerebrospinal fluid (CSF) or S. pneumoniae cultured from blood with radiological and/ or clinical features of meningitis. Lower respiratory tract infection (LRTI) was defined as S. pneumoniae identified in pleural/ empyema fluid or in blood with a radiological and/or clinical diagnosis of pneumonia. Septicemia was defined as S. pneumoniae cultured in blood with no clear focus of infection.
Comorbidity was defined as presence of a high-risk condition as defined in the Green Book on Immunization [6] .
Cases were classified into 4 vaccine groups according to serotype: PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, 23F), additional PCV13 serotypes (1, 3, 5, 6A, 7F, 19A), non-PCV13 serotypes, and unknown serotypes (typically due to nonreferral, or unsuccessful recovery after transport to the NRL).
Data Analysis
Annual IPD-related mortality rates were calculated by dividing the number of IPD-related deaths in the vaccine-eligible cohort for each surveillance year with population estimates for the vaccine-eligible cohort in that year. Surveillance years (eg, 2004-5) were defined from 4 September to 3 September of the following year. Population denominators were obtained from the Office for National Statistics. The vaccine-eligible cohort increased from 3 birth cohorts in 2006-2007 to 5 in 2008-2009 and subsequent years. Children aged ≥5 years were not routinely followed up with detailed questionnaires and, therefore, were not included in the analysis. Anonymized data, which were mainly descriptive, were exported to Stata software version 11.0 (StataCorp, College Station, Texas) for analysis. Categorical variables were described as percentages with binomial 95% confidence intervals (CIs) and compared using the χ 2 test or Fisher exact test. Continuous variables that did not follow a normal distribution were described as median with interquartile range (IQR) and compared using the Mann-Whitney U test. (Table 1 ). There were no significant differences between these groups in terms of age, serotype group distribution, or comorbidity prevalence, but meningitis was more prevalent among children who died in hospital (55/96 [57%] vs 17/53 [32%]; P = .003).
Serotypes
Of the 132 (88%) serotyped isolates, 35 distinct serotypes were identified, with no serotype predominance (Supplementary Table 1 ). PCV7 serotypes were associated with 23 of 132 (17%) deaths with known serotype, of which 43% (10/23) occurred in the first year after PCV7 introduction. PCV7 serotypes were responsible for only 3 of 14 (21%) deaths in 2013-2014.
The additional 6 PCV13 serotypes were responsible for 45 (34%) deaths, accounting for 23% ( The non-PCV13 serotypes were responsible for 49% (64/132) of deaths overall and 73%-92% of all IPD-related deaths after PCV13 introduction. The main serotypes after PCV13 introduction were 23B (n = 6), 22F (n = 5), 24F (n = 5), 33F (n = 5), 6C (n = 5), 8 (n = 5), 38 (n = 5), 15B (n = 4), 15C (n = 4), and 11A (n = 4).
Vaccination Status
Of the 112 children in the age group eligible for vaccination, only 72 (64%) had been appropriately immunized according to their age, including 5 of 17 (29%) PCV7-eligible children who died of PCV7-type IPD and 26 of 32 (81%) PCV13-eligible children who died of PCV13-type IPD. Vaccine uptake was lowest in those eligible for the initial PCV7 catch-up for <2-year-olds 
Mortality Rate
Annual IPD-related mortality rate in PCV-eligible children over the 8-year period was 0.58/100 000 children, including 0.59/100 000 in boys and 0.56/100 000 in girls. IPD-related mortality rate declined from 1. . Three deaths were due to PCV7 serotypes, including 2 infants with serotype 19F IPD who were too young to be immunized and one fully immunized toddler with serotype 14 IPD and asplenia diagnosed at postmortem. Eight other deaths (2 neonates, 3 aged 1-11 months and 3 older children) were due to NVT, with no serotype predominance, and 4 (50%) had underlying comorbidities.
CLINICAL PRESENTATION
Of the 150 IPD-related deaths, meningitis was the most common clinical presentation (n = 71 [47%]), followed by LRTI (n = 43 [29%]) and septicemia (n = 36 [24%]) (Table 1) . Notably, the clinical presentation did not vary by vaccine group (Figure 3) .
COMORBIDITIES
A third (53/150 [35%]) of children had an underlying comorbidity, which did not vary with age (range, 30%-50%). *Twelve children died of other causes, including group A streptococcal disease (n = 2), traumatic head injury (n = 2), aspiration pneumonia (n = 2), enterococcal meningitis, septic abortion following maternal chorioamnionitis, stillbirth following intrauterine hypoxia due to maternal infection, cardiomyopathy, severe gastroenteritis, and nonaccidental injury. **Cause of death in children who survived IPD but died later of another cause included 1 case each of Escherichia coli septicemia, varicella pneumonia, hemorrhagic shock following bowel obstruction, chronic liver disease, meningococcal septicemia, group A streptococcal septicemia, and unknown. Abbreviations: IPD, invasive pneumococcal disease; SUDI, sudden unexpected death in infancy.
The main comorbidities included premature birth (n = 18 [12%]; including 5/18 [28%] who had been born at <32 weeks' gestation), especially in children who developed IPD in the first year of life, and congenital heart disease (n = 13
[9%]). The range of different comorbidities increased with age (Table 1) ) occurred in <3-month-olds, including 20 with early-onset (EO) disease (0-6 days old). Five infants with EO disease (25%) had been born prematurely with no other significant comorbidities, while 8 infants with late-onset (LO; age 7-89 days) disease had comorbidities (8/22 [36%]), including premature birth only (n = 6), chromosomal disorder (n = 1), and chronic respiratory disease (n = 1). Clinical presentation also did not vary significantly between EO and LO deaths for meningitis (40% vs 55%), septicemia (25% vs 18%), or LRTI (35% vs 27%). The serotype distribution was also unremarkable; in 2013-2014, of the 3 EO and 2 LO fatalities, one each (both 19F) was due to a PCV7 serotype.
DISCUSSION
In England and Wales, IPD in young children is rarely associated with a fatal outcome, with only 150 reported deaths in 10 birth cohorts over 8 surveillance years. The overall CFR was 4.8%, with 59% of deaths occurring in infants, mainly <3-month-olds (28%), who were too young to benefit from the infant immunization program. Overall, 35% had an underlying risk factor for IPD, mainly premature birth (12%) and congenital heart disease (9%). Meningitis was responsible for 47% of IPD-related fatalities and, remarkably, clinical presentation did not vary by vaccine serotype group. PCV introduction was associated with a 69% reduction in IPD-related mortality in children aged <5 years since the first year of the immunization program. The actual reduction is likely to be greater if we had been able to compare with pre-PCV7 rates. Currently, nearly all deaths are due to serotypes that are not included in the licensed PCVs.
Population-based studies have consistently reported significant reductions in vaccine-type IPD after PCV7, PCV10, or PCV13 introduction [7] . Replacement disease with nonvaccine serotypes occurs, but the reduction in overall IPD rates remains positive [7] .
There are nearly 100 serologically distinct pneumococcal serotypes, each with different propensities for carriage, disease, clinical presentation, disease severity, and death [7] [8] [9] [10] [11] . In older children and adults at least, several vaccine and nonvaccine serotypes have been associated with more severe disease and death [12, 13] . It is, therefore, not surprising that the changes in serotypes causing IPD following the introduction of 2 highly immunogenic PCVs would affect disease characteristics and outcomes. PCVs were developed to protect against the most virulent serotypes and it was hoped that any replacing serotypes would have lower invasive potential. This assertion is partly true in that nonvaccine serotypes have only partly replaced the large niche in IPD cases left by the PCV serotypes [4] . In Spain, significant declines in IPD-related mortality rates have been reported in adults following both PCV7 and PCV13 introduction [14] . In children, such impact has been more difficult to demonstrate because of the small number of childhood cases and deaths. While confirming the low CFR in children with IPD, we also found a measurable decline in IPD-related childhood mortality rates after both PCV7 and PCV13 introduction.
A remarkable finding in our study was the consistency of clinical presentations with the different vaccine serotype groups among fatal cases. After PCV7 introduction in England and Wales, an increase in the additional PCV13 and other serotypes was observed [3] , along with an increase in LRTI presentations and a decrease in the other presentations [15] , yet nearly half the IPD-related deaths remained due to meningitis, irrespective of the vaccine serotype group responsible. Population-based studies have identified significant associations between specific pneumococcal serotypes and death among patients presenting with septicemia [12] and pneumonia [13] but not with meningitis [11, 13] . This contrasts with experimental animal models of meningitis, where serotype-specific differences in survival, brain damage, and inflammatory responses have been observed [16, 17] . In the United States, a recent study found that the number of children with pneumococcal meningitis did not change after PCV13 replaced PCV7, and there were no significant differences in presenting features, laboratory parameters, CSF findings, intensive care requirement, mechanical ventilation, neurosurgery, complications, or death, even though the proportion of meningitis cases due to PCV13 serotypes halved after PCV13 introduction [18] . The authors also found similar sequelae rates among survivors of PCV13 and non-PCV13 meningitis [18] . Reports of PCV7 and PCV13 impact on the incidence of childhood pneumococcal meningitis have been variable, with some regions finding significant reductions, while others reporting no measurable impact, partly because this is a rare disease with small numbers of cases, even in population-based studies [17] [18] [19] [20] [21] . It is likely that, while PCVs may have an impact on circulating pneumococcal serotypes, once pneumococcal meningitis develops, the clinical course and outcomes are less dependent on the responsible serotype and more dependent on host-related factors.
A major risk factor for death in children with IPD is the presence of underlying comorbidities. We have previously reported that, following PCV7 introduction, clinical presentation with meningitis and the presence of comorbidity were independent risk factors for death in children with IPD [15] . IPD-related CFR was 8.5% in children with comorbidities compared with 3.5% in those without [15] . One-third of our fatal cases had an underlying comorbidity compared to an overall prevalence of 15% among children with IPD after PCV7 introduction, where malignancy/immunosuppression and congenital heart disease predominated [15] . In <3-month-olds, we previously reported meningitis to be the only independent risk factor for death [22] .
We also found lower immunization uptake among our fatal cases compared with national coverage for children of a similar age [23] , possibly reflecting poor utilization of the free national health service and potentially contributing to delayed presentation to hospital during the acute illness. The higher comorbidity prevalence among fatal cases may also have contributed to delayed immunization and the poor outcomes. It is, however, reassuring to note that overall cases and deaths due to vaccine serotypes have declined. In 2013-2014, the 3 deaths related to PCV7 serotypes occurred in infants who were too young to be immunized or in those who had an underlying high-risk comorbidity. These cases, however, do indicate that PCV7 serotypes continue to circulate in England and Wales, albeit at low rates. Among the NVT fatalities, no particular serotype predominated after PCV13 introduction; indeed, many of these serotypes have emerged among IPD cases only after PCV introduction [4] .
The strength of this study lies in the prospective national follow-up of all children with IPD in the vaccine-eligible cohort, with high case ascertainment and questionnaire completion rates, along with detailed multisource data for fatal cases, including postmortem reports and death registration records. Because so few children die of IPD, it is important that all fatal cases are identified and thoroughly followed up, preferably in a large population cohort and over a long period of time. The low CFR is reassuring but the small numbers mean that any observed differences and trends must be interpreted with caution. We also have no data childhood deaths prior to PCV7 introduction for comparison, or on long-term complications in IPD survivors, especially those with meningitis.
Nonetheless, there are important lessons to be learned. PCV13-type IPD and PCV13-related deaths are currently rare and should continue to decline with the ongoing childhood immunization program. Currently, most IPD-related childhood deaths are due to non-PCV13 serotypes or occur in infants too young to be protected through vaccination, suggesting that additional strategies will be required. In particular, >10% of deaths occurred in the first week of life, where perinatal transmission is likely to have occurred [22] . Streptococcus pneumoniae is an uncommon but recognized cause of puerperal sepsis, with significant maternal and infant morbidity and mortality [24] , as also evidenced by the stillbirths and septic abortions identified in our surveillance, where S. pneumoniae was isolated from a normally sterile site at postmortem (Figure 1 ). Unlike group B streptococci, however, S. pneumoniae rarely (<1%) colonizes the female genital tract but has a very high infant invasion to maternal colonization ratio [22] . Clinicians should, therefore, consider empiric antibiotic treatment if they identify pregnant women with genital tract colonization or neonatal colonization at birth [25] . The finding that more than one-third of children (mainly infants) died outside the hospital or in the emergency department suggests either a very rapid onset or parental failure to recognize the warning symptoms and signs of serious infection. Raising awareness may improve earlier recognition of the sick child, leading to earlier treatment with better outcomes.
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